Valeant Pharmaceuticals International, Inc. (TSE:VRX) (NYSE:VRX) Director Schutter Richard Urbain De acquired 10,000 shares of the company’s stock in a transaction dated Friday, November 17th. The stock was purchased at an average cost of C$14.33 per share, for a total transaction of C$143,300.00.

Shares of Valeant Pharmaceuticals International, Inc. (TSE:VRX) traded up C$0.52 during midday trading on Tuesday, reaching C$20.46. The company’s stock had a trading volume of 2,329,876 shares, compared to its average volume of 1,437,482. Valeant Pharmaceuticals International, Inc. has a 1 year low of C$11.20 and a 1 year high of C$24.97.

WARNING: This news story was posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at

A number of equities research analysts have recently issued reports on VRX shares. Royal Bank Of Canada cut their target price on Valeant Pharmaceuticals International to C$22.50 and set a “sector perform” rating on the stock in a research report on Friday, October 20th. TD Securities raised Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating and set a C$25.50 price target on the stock in a research report on Wednesday, November 8th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Valeant Pharmaceuticals International presently has a consensus rating of “Hold” and an average target price of C$22.50.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with's FREE daily email newsletter.